ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Data From Anthera's Plasma Trial To Be Presented As Late Breaker At American College Of Cardiology Scientific Sessions
Anthera Pharmaceuticals,
Inc., a privately held biopharmaceutical company developing
anti-inflammatory drugs, announced that data from the Phase II trial
of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for
the treatment of coronary heart disease will be presented as a late breaker
at the 2008 American College of Cardiology 57th Annual Scientific Session
on Monday, March 31, 2008 in Chicago, Illinois.
The Phase II trial known as PLASMA (Phospholipase Levels And
Serological Markers of Atherosclerosis) was a multi-center, randomized,
double-blind, placebo-controlled trial that enrolled approximately 400
patients with stable coronary heart disease in the U.S. and Ukraine.
Subjects were randomized to receive one of four different doses of A-002 or
placebo for up to eight weeks. Patients also received doctor-determined
standard of care therapies. The primary endpoint was a reduction in
secretory phospholipase A2 (sPLA2). The study also evaluated the effect of
Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as
well as inflammation in patients with stable coronary heart disease.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held company committed to
developing and commercializing clinical pharmaceutical products that
address unmet medical needs of patients with life-threatening, chronic and
acute inflammatory diseases and autoimmune disorders. The Company has
acquired from Eli Lilly and Company and Shionogi & Co.‚ Ltd. worldwide
rights (excluding Japan) to a series of clinical and pre-clinical compounds
that inhibit the enzymatic activity of members of the phospholipase (PLA2)
family -- a group of enzymes responsible for the release of arachidonic
acid and subsequent production of leukotrienes‚ prostacyclins and other
mediators of inflammation. These highly potent compounds inhibit novel‚
upstream steps in the inflammation cascade and have the potential to
address a variety of diseases. The company has also acquired exclusive and
worldwide rights to a peptide fusion protein, A-623, for the treatment of
systemic lupus erythematosus (SLE) and other autoimmune diseases from
Amgen. For more information, please visit http://www.anthera.com.
Anthera Pharmaceuticals, Inc.
http://www.anthera.com
Datele de la Anthera plasmatice de proces pentru a fi prezentate ca târziu spãrgãtor de la Colegiul American de Cardiologie sesiuni ºtiinþifice - Data From Anthera's Plasma Trial To Be Presented As Late Breaker At American College Of Cardiology Scientific Sessions - articole medicale engleza - startsanatate